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Abstract
Background: Gaucher disease (GD) is the most common lysosomal storage disorder (LSD). Based on a deficient b-
glucocerebrosidase it leads to an accumulation of glucosylceramide. Standard diagnostic procedures include measurement
of enzyme activity, genetic testing as well as analysis of chitotriosidase and CCL18/PARC as biomarkers. Even though
chitotriosidase is the most well-established biomarker in GD, it is not specific for GD. Furthermore, it may be false negative
in a significant percentage of GD patients due to mutation. Additionally, chitotriosidase reflects the changes in the course of
the disease belatedly. This further enhances the need for a reliable biomarker, especially for the monitoring of the disease
and the impact of potential treatments.
Methodology: Here, we evaluated the sensitivity and specificity of the previously reported biomarker Glucosylsphingosine
with regard to different control groups (healthy control vs. GD carriers vs. other LSDs).
Findings: Only GD patients displayed elevated levels of Glucosylsphingosine higher than 12 ng/ml whereas the comparison
controls groups revealed concentrations below the pathological cut-off, verifying the specificity of Glucosylsphingosine as a
biomarker for GD. In addition, we evaluated the biomarker before and during enzyme replacement therapy (ERT) in 19
patients, demonstrating a decrease in Glucosylsphingosine over time with the most pronounced reduction within the first 6
months of ERT. Furthermore, our data reveals a correlation between the medical consequence of specific mutations and
Glucosylsphingosine.
Interpretation: In summary, Glucosylsphingosine is a very promising, reliable and specific biomarker for GD.
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Introduction
Gaucher disease (GD) is the most common lysosomal storage
disorder (LSD), with an estimated prevalence in Caucasians
ranging from about 1:40,000 to 1:60,000, although a current
newborn screening in Szeged, Hungary suggests a higher
prevalence of 1:13,341 [1–2]. LSDs are generally characterized
by a genetic defect in proteins and enzymes involved in the
lysosomal degradation of macromolecules into smaller compounds
resulting in the accumulation of non-degraded macromolecules
[3]. In GD this results in the accumulation of glucosylceramides as
the enzyme b-glucocerebrosidase is impaired. This causes a
compensatory lipid re-uptake by macrophages which likewise
cannot degrade glucosylceramides and thus enlarge and evolve
into the disease-specific ‘‘Gaucher cells’’. They are the hallmark of
the disease [4].
Depending on onset and symptoms, GD can be classified as
non-neuronopathic, which is the mildest and most common
phenotype in GD; the acute, neuronopathic form, which
represents the severest form of the disease and is fatal within a
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few years; and the sub-acute, chronic neuronopathic form [5–6].
Non-neuronopathic GD is the most common disease manifesta-
tion in the Ashkenazi Jewish population and with a frequency of
up to 1:1,000, it is far more common than in the European
Caucasian population [7]. Genotype–phenotype correlations have
been described in the literature. The most common examples are
the mutation N370S usually detected in patients with non-
neuronopathic GD carrying a milder burden of disease whereas
e.g. the mutation L444P is more frequently seen in the more severe
neuronopathic form of GD [1].
Established treatment options entail either enzyme replacement
therapy (ERT) with recombinant glucocerebrosidase (Cerezy-
meTM, Genzyme Corporation, Cambridge, MA USA; or
VPRIVTM, Shire HGT, Lexington, MA USA) that supplement
the missing or malfunctioning enzyme or substrate reduction
therapy (SRT) with Miglustat (ZavescaTM, Actelion Pharmaceu-
ticals Ltd, Allschwil, Switzerland) which reduces production of the
available substrate.
Current diagnostic steps comprise the measurement of b-
glucocerebrosidase enzyme activity in fibroblasts and leucocytes,
supported by the detection of the mutation and determination of
chitotriosidase and CCL18/PARC [8]. However, enzyme activity
levels cannot be used to reliably determine disease severity. The
routinely available biomarkers, chitotriosidase and CCL-18, are
epiphenomena caused by activation of macrophages after uptake
of glucosylceramide. Therefore, they do not reflect the patho-
physiology of the disease and reflect only to a limited extent the
disease activity or response to therapy. While GD patients display
a massive increase in chitotriosidase, patients with other LSDs
exhibit elevated chitotriosidase levels to a lesser extent. However
this limits the significance and value of this measurement [9]. In
male Fabry patients Vedder and colleagues found evidence of
elevated chitotriosidase levels which was reduced to normal after
onset of treatment reflecting the lipid accumulation in Fabry
patients in macrophages prior to therapy [10]. Not only lysosomal
storage disorders may cause an increase in chitotriosidase,
peroxisomal disorders like the X-linked cerebral adrenoleukodys-
trophy may also cause an elevation of this biomarker, which
recently was reported to be able to monitor and predict the
prognosis of patients with X-linked cerebral adrenoleukodystrophy
receiving allogeneic hematopoietic stem cell transplantation [11].
Furthermore, subjects, including those with GD, may have a
chitotriosidase activity deficiency due to a 24–base pair (bp)
duplication in the chitotriosidase gene. Obviously, these individ-
uals cannot be monitored by the measurement of plasma
chitotriosidase activity [12–13]. The frequency of the homozygous
24-bp duplication in the chitotriosidase gene depends on the
ethnicity and can vary between 6% and nearly 35% in the Latino
population (unpublished data). In these cases the marker CCL18 is
used [14–15]. However, elevated levels of CCL18 were also found
to be associated with a variety of diseases, such as different types of
cancer and inflammation of joints, lungs and skin (e.g. rheumatoid
arthritis, hypersensitivity pneumonitis and atopic dermatitis, for
details see review by Schutyser and colleagues) [16]. For example,
the ascitic fluid of patients suffering from ovarian cancer contains a
significantly elevated level of CCL18 compared to patients without
this carcinoma (Budd-Chiari syndrome) [17]. Since it attracts and
activates specific immune cells CCL18 plays a role in tumor
suppression. Furthermore, children having acute lymphocytic
leukemia are found to exhibit elevated levels of CCL18 [18].
Hence, plasma levels of CCL18 do not reflect one particular
clinical symptom, but are rather a reflection of the total body
burden of Gaucher cells.
Therefore, there is a definite need for a sensitive and specific
biomarker, which would need to be feasible for diagnosis of GD as
well as follow-up monitoring of GD patients.
Biomarkers should ideally reflect or be involved in the
pathophysiology of the given disease. They should change in
parallel with the burden of the disease and effectively discriminate
between affected and non-affected probands. Some parameters
being involved in the pathologically changed metabolic pathway
had been analysed in the past: Groener et al. have analysed the
ratio of Glucosylceramide/Ceramide (GlcCer/Cer) to discrimi-
nate between GD patients and healthy patients [19]. GlcCer and
Cer were measured with high performance liquid chromatography
(HPLC) essentially as described by Groener and colleagues [20].
The level of GlcCer was found to be different although ceramide
levels were not significantly different in the plasma of treated and
untreated GD type I patients.
Recently, Dekker and colleagues introduced glucosylsphingo-
sine, which was first reported to be elevated in the cerebrum and
cerebellum of patients with acute and subacute neuronopathic GD
[21], as a new marker in the blood plasma of GD patients [22].
The authors demonstrated that plasma glucosylsphingosine levels
were correlated well with chitotriosidase and CCL18. Further-
more, treatment of GD resulted in a clear glucosylsphingosine
reduction, similar to chitotriosidase. Currently, there are also
approaches to identify feasible markers for bone turnover in GD
[23].
In order to establish a sensitive and specific biomarker for GD,
we compared mass spectra of the plasma of healthy controls and
GD patients using HPLC and tandem mass spectrometry. Mass
spectra that differed most between patients and controls were
analysed in more detail. The resulting biomarker, which was
patented in June 2011 (PCT/EP2012/002409; Arndt Rolfs,
Hermann Mascher), was Glucosylsphingosine. We identified this
compound independent of Dekker and colleagues as a reliable,
sensitive and specific biomarker for GD in a large cohort of GD
patients. Furthermore, we evaluated whether Glucosylsphingosine
is related to the specific genotypes and is reliable for long-term
monitoring of the efficiency of therapy.
Results
Overall, 551 non-Jewish, Caucasian subjects were analysed.
The population consisted of 272 (49.6%) males and 272 (49.6%)
females, in 7 cases the gender was not known. In total 148 healthy
controls were compared to 98 genetically diagnosed GD patients
(for detailed information see Table S1), 13 GD carriers, and 262
patients with other LSDs (Table 1). Patients with other LSDs were
suffering from Niemann-Pick-Type C disease, Krabbe disease,
Hunter disease and Fabry disease. There were significant
differences in the gender distribution when comparing the four
sub-cohorts (p = 0.029) as more males were in the GD carrier
group than in the other three sub-cohorts. There was a significant
age difference as the healthy control group and the GD patient
group were younger than the GD carriers and patients with other
LSDs (p = 0.012). The healthy controls, 81 (54.7%) males and 67
(44.8%) females, had a median age of 29.0 years, while the GD
carriers, 8 (64.7%) males and 5 (35.3%) females, had a median age
of 35.0 years. Of the GD patients 66 (52.26%) were males and 56
(47.8%) were females and had overall a median age of 29.0 years.
The patients suffering from other LSDs had a median age of 38.0
years and consisted of 117 (44.8%) males and 144 (55.2%) females.
According to the established protocol Glucosylsphingosine
(chemical structure depicted in Figure 1) measurements were
carried out in blood plasma samples. Exemplary measurements
Glucosylsphingosine as a Biomarker for GD
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are depicted in Figure 2, comparing Glucosylsphingosine mea-
surements of a healthy control (Figure 2A, blue line, first peak in
chromatogram), a mildly affected GD patient (Figure 2B), and a
severely affected GD patient (Figure 2C) compared to the internal
standard (Figure 2, red line, second peak in chromatogram).
Subsequently, Glucosylsphingosine values for all four sub-
cohorts were statistically analysed. Several cut points were
considered and a careful analysis yielded a cut-off of 12 ng/ml
with an ideal sensitivity and specificity of 100% (data for other
calculated cut-offs not shown). This observation was independent
of gender (Figure 3B), levels of Glucosylsphingosine being similar
in male and female GD patients. Notably, neither healthy
probands, patients with other LSDs nor GD carriers exhibited
pathologic values above the cut-off of 12 ng/ml (Figure 3A). Only
GD patients displayed Glucosylsphingosine values above the
normal range.
Both Chitotriosidase and CCL18 were quantified as well, and
sensitivity and specificity were compared to those of Glucosyl-
sphingosine (Table 2). Chitotriosidase had a sensitivity of 91.7%
and a specificity of 86.1%. In our analysed patients and controls
CCL18 had a sensitivity of 76.2% and a specificity of 79.4%.
Receiver Operating Characteristics (ROC) analysis was carried
out to evaluate the accuracy of Glucosylsphingosine compared to
chitotriosidase (Figure 4A) and CCL18 (Figure 4B). The corre-
sponding area under the curve (AUC) and confidence intervals
(CI) are 1.00 (1.00–1.00) for Glucosylsphingosine, 0.96 (0.89–0.98)
for chitotriosidase and 0.86 (0.80–0.93) for CCL18 (Table 2). The
accuracy of Glucosylsphingosine is significantly better than
chitotriosidase (p = 0.027) and CCL18 (p,0.001).
Aside from the measurements of Glucosylsphingosine, chito-
triosidase and CCL18 also GD genotyping was performed. A
broad spectrum of different mutations was detected for the 98 GD
patients where DNA was available, 45 different mutations in total.
N370S (32.5%), L444P (22.1%) and RecNciI (8.0%) comprising
about 2/3 of all mutations.
We found correlations between the two most frequent mutations
N370S and L444P on the one hand and levels of the biomarker
Glucosylsphingosine on the other hand (Table 3). Patients affected
by the mutation L444P demonstrated higher blood plasma levels
of Glucosylsphingosine (median 184.5 ng/ml) than those affected
by the milder N370S mutation (median 143.1 ng/ml). Further-
more, Glucosylsphingosine was higher in homozygous (median of
143.1 ng/ml in N370S/N370S and 184.5 ng/ml for L444P/
L444P) than in compound heterozygous (median of 77.1 ng/ml in
N370S compound heterozygous and 107.0 ng/ml in L444P
compound heterozygous) GD mutations.
For 19 GD patients we were able to monitor Glucosyl-
sphingosine before and after start of ERT (Figure 5), blood was
drawn before starting the infusion. Testing of 3 patients revealed
that the biomarker in plasma was stable at 4uC up to at least 22
days and hemolytic samples of EDTA-blood yielded identical
results compared to those samples immediately processed after
sampling. For two patients we collected plasma at several time
points (24 h, 12 h, 6 h before ERT, right before the start of ERT
infusion, 6 h, 12 h, 24 after ERT). The samples had a range of
68% within the first 24 hours of ERT, indicating that there was
no immediate effect of ERT on the Glucosylsphingosine levels.
Overall, the patients ranged from 50–250 ng/ml prior to ERT.
Time point zero by definition characterises the first measurement
after start of therapy, which not always represented the first day of
ERT but also weeks after the initial treatment. This is due to the
fact that this part of the study was undertaken in retrospective and
blood samples at onset of therapy was not available for all patients.
Thus, Glucosylsphingosine was already reduced at time point zero
instead of decreasing after commencement of therapy.
For all patients a significant reduction after start of therapy and
over time was detected (Figure 5A), e.g., the very striking graph of
Table 1. Comparison of the four cohorts.
Healthy Controls GD Carriers GD Patients Other LSDs
N individuals 148 13 129 261
% 26.9 2.4 23.4 47.4
N measures 163 15 456 340
Age in years:
Median 29 35 29 38
Interquartile Range (5–48) (31–59) (8–44) (19–50)
Number of Cases (n = 141) (n = 13) (n = 119) (n = 238)
male female male female male female male female
n 81 67 8 5 66 56 117 144
% 54.7 44.8 64.7 35.3 52.2 47.8 44.8 55.2
Age in years:
Median 26 34 34 39 24 32 31 44
Interquartile Range (5–50) (5–47) (26–52) (33–70) (8–45) (10–43) (14–49) (25–53)
Healthy controls, GD carriers, GD patients and patients with other LSDs with respect to age and gender. 148 controls and 261 patients suffering from other LSDs were
compared to 13 GD carriers and 129 patients suffering from GD.
doi:10.1371/journal.pone.0079732.t001
Figure 1. Chemical structure of Glucosylsphingosine. This
substance was only analysed by HPLC-MS/MS with high sensitivity
and specificity of diagnosing GD.
doi:10.1371/journal.pone.0079732.g001
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Figure 2. Analysis of Glucosylsphingosine and Internal Standard in different samples. Measurement of Glucosylsphingosine (first peak in
chromatograms (blue), second peak in chromatograms is Internal Standard (red)) in a healthy control (1.71 ng/ml) (A) and two differently affected
Glucosylsphingosine as a Biomarker for GD
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patient #34, whose Glucosylsphingosine values decrease after start
of ERT, but increases significantly when the patient had to
discontinue therapy due to ERT shortage. The graphs #10, #244
and #259 display a clear reduction of Glucosylsphingosine from
an average 200 ng/ml before onset of therapy to levels below
50 ng/ml after onset of therapy. Overall, the vast majority of
patients feature Glucosylsphingosine values below 50 ng/ml after
onset of ERT (Figure 5).
A linear mixed-model regression analysis for Glucosylsphingo-
sine before and after therapy was carried out (Table 4). Only
patients with Glucosylsphingosine measurements before and after
onset of therapy were included in the analysis. On average patients
started with a concentration of 50.0 ng/ml Glucosylsphingosine
before treatment. The most striking reduction of Glucosyl-
sphingosine occurs right after the start of therapy (47.3%,
p,0.001) and within the first 6 months (47.3%), although
reduction over time is also highly significant (p,0.0001).
Discussion
In 1989 Rosengren and colleagues published a comparative
analysis of glycosphingolipid patterns, especially lyso-sulfatide, in
the normal brain and in patients suffering from Metachromatic
Leukodystrophy [24]. They concluded that lyso-glycosphingolipids
did not contribute to disease pathology as their findings supported
the idea of de-novo-synthesis of lyso-glycosphingolipids from
sphingosine. Likewise Lloyd-Evan and colleagues concluded from
their experiments with glycosphingolipids and calcium that they
may not contribute to disease pathology, but could play a possible
role in treatment [25]. However, these experiments were
conducted with healthy Wistar rats, not suffering from a specific
LSD. This is contrary to the older findings of Atsumi and
colleagues, who argued for a pathologic role of glycosphingolipids
[26]. This is also supported by more recent studies, where
Glucosylsphingosine in particular was investigated and found to be
responsible for neuronal cell death [27]. The presence of
glucosylceramide and glucosylsphingosine in the cerebrum and
cerebellum of five infantile and juvenile Gaucher patients has been
described by Nilsson and Svennerholm (1981), demonstrating the
highest levels of glucosylcermide and glucosylsphingosine in the
severest cases [21].
Here, Glucosylsphingosine was analysed in a large, non-Jewish,
Caucasian cohort, comprising healthy probands, GD patients, GD
carriers and patients with other LSDs. Not only did Glucosyl-
sphingosine distinguish between healthy probands and those with
GD disease with a cut-off of 12 ng/ml, but also between GD
patients and GD carriers. In addition, the marker additionally
proved to be specific for GD as patients with other LSDs did not
shown signs of elevated Glucosylsphingosine (Figure 3). Further,
Glucosylsphingosine proved to be independent of gender, with
similar levels of the biomarker in both genders. This finding is in
contrast to FD, where even symptomatic females display levels of
lyso-Gb3 in a range that was 10-times lower than in males and in
some cases even close to normal [28]. Furthermore, Glucosyl-
sphingosine correlated with the genotype. Patients with N370S
displayed lower levels of Glucosylsphingosine than those with
L444P, which is known to be more frequent in patients with a
more fatal course of disease [29]. Furthermore, patients homozy-
gous for either N370S or L444P exhibit higher values for
Glucosylsphingosine than those who were compound heterozy-
gous with only one of those mutations (Table 3). This is in line with
the findings of Dekker at al. who measured Glucosylsphingosine as
well and found modest increases in Glucosylsphingosine in mildly
affected patients [22]. Results for Glucosylsphingosine in GD
patients were comparable to the results presented here, the median
value for Glucosylsphingosine in type 1 GD patients was
230.7 nM, which approximately corresponds to 92.28 ng/ml
and is in line with our results. However, there are differences in
both measurement techniques. The method we have chosen for
the measurement of direct Glucosylsphingosine might be of
individuals with GD (B and C). Medium level of Glucosylsphingosine is shown for the first patient (B: 17.1 ng/ml) and a high level of
Glucosylsphingosine for the second (C: 319 ng/ml). Please note the changed scale in (C).
doi:10.1371/journal.pone.0079732.g002
Figure 3. Glucosylsphingosine levels in sub-cohorts. Level of Glucosylsphingosine is illustrated in the entire cohort (A) and separated
according to gender (B). Glucosylsphingosine in GD patients was compared to healthy controls, GD carriers and patients with other LSDs. The
horizontal bar marks the cut-off for pathological Glucosylsphingosine values above 12 ng/ml. Notably, only GD patients feature pathological values
of Glucosylsphingosine and additionally Glucosylsphingosine is not gender-dependent (B; dark green representing males and orange females).
doi:10.1371/journal.pone.0079732.g003
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importance for the discrimination capacity of this marker. It is
important to understand that glucosylsphingosine present in the
plasma mainly consists of a sugar moiety and a ceramide moiety.
Further, the ceramide moiety consists of a sphingosine and a fatty
acid. Using older technology lipids are extracted and ceramide
and glucosylceramide are deacylated by alkaline hydrolysis thus
forming the lyso form, i.e. Glucosylsphingosine [30]. Subsequent-
ly, the Glucosylsphingosine thus produced is labeled with a
fluorescence dye by derivatization with O-phthaldialdehyde (OPA)
at the primary amine group. Afterwards the derivatized sphingoid
bases were separated by reverse phase HPLC and measured by a
fluorescence detector. With this technology one is able to detect
total Glucosylsphingosine consisting of free Glucosylsphingosine
and Glucosylsphingosine, but is not able to distinguish a level of
free Glucosylsphingosine from a level of Glucosylsphingosine in a
sample from a subject. Importantly, each primary amine
circulating in the plasma, being sufficiently lipophilic to be
extracted concomitantly with Glucosylsphingosine using an
organic solvent is labeled accordingly. Thus, this may disturb
the detection of cleaved Glucosylsphingosine. The level of said
total Glucosylsphingosine after cleavage of the various fatty acid
moieties from the NH2 group of the Glucosylsphingosine is usually
in a range of from 5 to 30 mg per mL plasma or serum. We were
able to measure free Glucosylsphingosine in the plasma without
performing a cleavage of the fatty acid moieties. Therefore, this
procedure allowed reducing the detection limit to 0.25 ng/ml (95
percentile). The putative advantage of our slightly different
measurement approach of Glucosylsphingosine compared to the
method of Dekker and colleagues is the ability to differentiate
between GD patients on the one hand and GD carriers and
patients with other lysosomal storage disease on the other hand,
however this will have to be verified in future studies with a larger
cohort and more long-term data.
In comparison to chitotriosidase and CCL18, Glucosylsphingo-
sine proved to be 100% sensitive and 100% specific. The major
disadvantage of chitotriosidase is the prevalence of the 24 base-
Table 2. Sensitivity and specificity for different biomarkers with regard to diagnosis of GD.
Chitotriosidase (n=233) CCL18 Park (n =207) Glucosylsphingosine (n =521)
Cut point .145 .166 .12
Sensitivity 91.7% 76.2% 100.0%
Specificity 86.1% 79.4% 100.0%
AUC and 95%CI in ROC Analysis 0.94 (0.89–0.98) 0.87 (0.80–0.93) 1.00 (1.00–1.00)
So far Chitotriosidase is the standard biomarker for GD, however due to mutations in the Chitotriosidase gene, Chitotriosidase can be false negative, thus makes the use
of the far more unreliable marker CCL18 necessary. For assessment of chitotriosidase sensitivity and specificity 233 samples were analyses resulting in a sensitivity of
91.7% and a specificity of 86.1%. Overall 207 samples were analysed to evaluate the sensitivity and specificity of CCL18, which displayed a sensitivity of 76.2% and a
specificity of 79.4% each. We propose Glucosylsphingosine as a more specific and sensitive biomarker for GD as it yielded both a sensitivity and specificity of 100% in
521 analysed samples.
doi:10.1371/journal.pone.0079732.t002
Figure 4. ROC curve analysis for comparison of Glucosylsphingosine. Glucosylsphingosine (A; red line; area under the curve (AUC) = 1.00)
and Chitotriosidase (A; blue line; AUC=0.96) as well as Glucosylsphingosine (B; red line; AUC= 1.00) and CCL18 (B; blue line; AUC= 0.86) to
discriminate the accuracy of two values. Glucosylsphingosine is significantly more accurate than Chitotriosidase (A: p = 0.027, n = 228) and CCL18 (B:
p,0.001, n = 207).
doi:10.1371/journal.pone.0079732.g004
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pair duplication within approximately 6% of the normal
population, which contributes to false negative results (Table 2)
[9]. Another factor that complicates use of chitotriosidase, is the
fact that it is a by-product amassed in Gaucher cells and not
directly disease-related as Glucosylsphingosine is [31]. Since it
responds very slowly, requiring about 3–6 months after start of
treatment to start to decline, it hinders accurate monitoring by
chitotriosidase of therapeutic interventions. Importantly, we
observed a rapid and pronounced reduction of Glucosylsphingo-
sine directly after onset of therapy (Figure 5). The pathophysio-
logical relevance of a reduction of Glucosylsphingosine remains to
be illustrated. It is yet undetermined how the reduction of
Table 3. Glucosylsphingosine levels in patients carrying frequent Gaucher mutations.
Homozygotes Compound Heterozygotes
N370S
N individuals (%) 8 (6.2%) 70 (54.3%)
Median (IQR) Glucosylsphingosine 143.1 77.1
(96.6–236.3) (33.1–164.0)
L444P
N individuals (%) 16 (12.4%) 31 (24.0%)
Median (IQR) Glucosylsphingosine 184.5 107.0
(103.0–275.3) (70.5–246.0)
Comparison of the frequency and Glucosylsphingosine values (median and interquartile range (IQR)) in the mutation N370S predisposing for a benign phenotype and
the mutation L444P highly likely to cause severe GD. Notably, homozygous mutations are associated with higher Glucosylsphingosine values in both mutations. In the
mutation L444P, which is inherent in many severely affected GD patients, Glucosylsphingosine is higher than in patients with the mutation N370S. This indicates the
correlation of Glucosylsphingosine with the burden of the disease as homozygous individuals are more severely affected than compound heterozygous ones and
patients with L444P more than those with N370S. Of note, patients compound heterozygous for N370S/L444P were included in both compound heterozygous cohorts.
doi:10.1371/journal.pone.0079732.t003
Figure 5. Monitoring of enzyme replacement therapy by Glucosylsphingosine. Course of Glucosylsphingosine after onset of treatment, the
time point zero representing the first value after onset of therapy. The course for 19 GD patients undergoing ERT is shown. In summary the following
genotypes were detected: #256: N370S/N370S; #7, #8, #181, #242: N370S/L444P; #10, #113, #149, #154, #178, #184, #211 are N370S/other.
Two severely affected patients, 113 and 34, had been started with ERT for 10 months (pts. 113) and 4 months (pts. 34), respectively, but stopped due
to shortage of the treatment. With the beginning of the ERT Glucosylsphingosine dropped down immediately, however went back to the original
level after stopping of the ERT. After a second start with ERT 19 and 20 months, respectively, after initial starting the ERT the Glucosylsphingosine
concentration dropped down again.
doi:10.1371/journal.pone.0079732.g005
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Glucosylsphingosine during treatment correlates with clinical
improvement. Ongoing studies (Clinicaltrial.gov, NCT01331642)
will determine if the marker will allow the calculation of individual
dosages and improve the clinical outcome for each patient.
Overall, this highlights the potential of Glucosylsphingosine as a
reliable marker for monitoring.
In summary, Glucosylsphingosine is a very promising, reliable
and specific biomarker for GD. The marker is not only valid for
the primary diagnosis of GD patients but also able to reflect the
progress as well as improvement of the disease, e.g. when ERT has
been stopped in a patient, significant increase of the concentration
of the marker in plasma can be demonstrated within 3 weeks after
stopping the ERT, compared to 10 weeks in case of chitotriosidase
(data not shown). However, in order to characterise the correlation
with clinical phenotype, the response to ERT therapy, or even to
demonstrate differences in the efficiency of the different treatment
options available to the patients, Glucosylsphingosine has to be
analysed in further detail.
Methods
Patients and Blood Samples
Blood samples were obtained from patients undergoing
biochemical analysis or genetic testing for verification of a
suspected metabolic disease by the Albrecht-Kossel-Institute for
Neuroregeneration (AKos). All patients agreed for testing of their
blood samples. The protocol of the study has been approved by
the local Ethical Committee of the University Rostock. Patients
undergoing therapy were treated according to standard protocols.
Written informed consent was obtained from all participants.
Biochemical and Genetic Analysis
Standard analysis of GBA gene (for specific genotypes see Table
S1), CCL18/PARC and Chitotriosidase were performed accord-
ing to standard protocols [32–33].
Identification of Glucosylsphingosine as a Biomarker for
GD
Screening for potential biomarkers was carried out using
HPLC-MS/MS of blood plasma samples of 10 healthy subjects
and 10 GD patients with accurate mass MS-systems (Orbitrap XL)
and tandem MS systems. Differences between GD patients and
healthy people were carefully assessed with regards to substances
strongly increased in patients. Molecular weight and structure of
such substances were determined carefully. Peaks identified by
tandem MS/MS were measured using already known internal
standards as reference. Successive measurement in larger GD
cohorts ensued and after validating the robustness of Glucosyl-
sphingosine, measurement in healthy cohort, GD carriers, GD
patients and in patients with other LSDs followed.
After the first block of analysis of GD patients (where the
information healthy – not healthy was known) all other analyses
for Glucosylsphingosine were done blinded.
Method for Determination of Free Glucosylsphingosine
in Plasma
50 mL of the sample are mixed with 100 mL of Internal
Standard working solution (in EtOH), are thus mixed subsequently
using a DVX-2500 Multi-tube vortex device at 2500 rpm for
about 30 seconds. After centrifugation at 4000 rpm for 2 minutes
the clear supernatant was transferred into auto-sampler vials and
injected into the HPLC-MS/MS system. Mobile phase used for
gradient elution was 50 mM formic acid in water and 50 mM
formic acid in acetonitrile/acetone (1/1, v/v). HPLC flow was set
at 0.9 mL/min on an ACE 3 C8 column (5062.1 mm) at 60uC,
injection volume used was 5 mL. Retention time for the analyte
was approximately 3.4 minutes and for the internal standard (lyso-
Gb2) approximately 3.6 minutes. Lyso-Gb2 was checked in
regards to native concentrations in plasma and was found to be
at very low levels only, sufficient amount was added therefore
during sample preparation. The MS/MS system used was an API
4000 using electrospray ionization in MRM mode in positive
mode at 500uC for determination of free Glucosylsphingosine in
plasma. Quadrupole resolution was set at unit/unit, MRM
transitions used were 462 R 282 m/z for the analyte and 624
R 282 for the internal standard. Calibration was done from
0.4 ng/mL to 100 ng/mL in methanolic solution, QC samples
were spiked in plasma at levels of 1, 5, and 50 ng/mL.
Statistics
In order to compare the diagnostic value of the different
biomarkers and for the calculation of correlations between the
biomarkers, we first aggregated the data using the earliest
measured value of every marker for GD patients before therapy
and the highest value for non-GD for a particular patient if more
than one blood sample was available. This resulted in a sample of
148 healthy controls, 13 GD carriers, 129 GD patients and 261
patients with other LSDs.
The accuracy of values of the different biomarkers (Glucosyl-
sphingosine, chitotriosidase, enzyme activity and CCL18/PARC)
to discriminate patients with GD disease from patients without GD
was evaluated using Receiver Operating Characteristic (ROC)
curve analysis [34–35].
The area under the curve (AUC) and the 95% confidence limits
for the different biomarkers are reported in Table 2. Paired sample
statistical techniques were used for the comparison of two
biomarkers. The method exploits the mathematical equivalence
of the AUC to the Mann-Whitney U-statistic [36].
Table 4. Regression analysis for Glucosylsphingosine.
Time in
months
Glucosylsphingosine
(ng/ml)
Reduction in % compared
to 6 months before therapy
26 50.0 2
0 26.4 47.3
6 26.1 47.8
12 25.9 48.2
18 25.8 48.3
24 25.9 48.2
30 26.0 47.9
36 26.3 47.4
48 27.1 45.8
60 28.4 43.1
The analysis included all 19 patients for whom values before and after ERT were
available, details on the course of Glucosylsphingosine values are shown in
Figure 5. Time point zero represents the first value after onset of therapy. The
table shows regression based (linear mixed models) predicted values for
Glucosylsphingosine and reduction in % compared to 6 months before therapy.
To overcome the skewed distribution of measurements Glucosylsphingosine
values were logarithmised before regression analysis.
Glucosylsphingosine was reduced after onset of ERT. The largest reduction
occurred within the first 6 months after starting the ERT therapy. Patients
display a reduction of 47.8% after 6 months and of 43.1% after 60 months of
therapy.
doi:10.1371/journal.pone.0079732.t004
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The ROC curves were calculated using PASW Statistics 18,
Release Version 18.0.2 ( SPSS, Inc., 2009, Chicago, IL, www.
spss.com). The comparisons of ROC curves and the linear mixed
models were done using SAS software, Version 9.2 of the SAS
System for Windows ( 2008 SAS Institute Inc., Cary, NC, USA).
For analysing how Glucosylsphingosine changed over time in
GD patients, we analysed non-aggregated data for those patients
for whom we had more than one blood sample available (20 GD
patients). The first measurement under therapy for every patient
was set to time point zero. We used linear mixed-models for testing
if time dependent reduction – values after start of therapy
compared to values before therapy – were significant.
Supporting Information
Table S1 Genotypes for all included GD patients. GBA
cDNA accession number NP_000148.2; Traditional amino acid
residue numbering, which excludes the first 39 aminoacids of the
leader sequence, is provided and designed without the prefix ‘‘p’’.
All detected genotypes are listed and have been confirmed by
Sanger sequencing. The cohort is comprised of a non-Jewish,
Caucasian cohort of GD patients.
(PDF)
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